Abiopharma

Labeling changes approved for AUROBINDO PHARMA LTD. Active ingredient: ACETAZOLAMIDE. Decision date: 01/08/2026

Labeling changes approved for MYLAN. Active ingredient: ETHINYL ESTRADIOL; NORGESTIMATE. Decision date: 01/07/2026

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Equity Listing - Ordinary Shares: Issue and Allotment of Shares Pursuant to Exercise of Warrants

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Garner Ebun 🟡 adjusted position in 116.1K shares (1 derivative) of Erasca, Inc. (ERAS) at $5.59 ($1.1M) Transaction Date: Dec 15, 2025 | Filing ID: 008076

Director Grewal Harpreet 🔴 sold 186 shares of Penumbra Inc (PEN) at $312.64 Transaction Date: Jan 06, 2026 | Filing ID: 000002

Zeldin Robert K 🟡 adjusted position in 6.7K shares (1 derivative) of MeiraGTx Holdings plc (MGTX) at $7.73 Transaction Date: Jan 07, 2026 | Filing ID: 000002